A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

Inclusion Criteria: * PHASE I: Documented informed consent of the participant * PHASE I: Age: \>= 18 years and \< 55 years * PHASE I: Ability to read and understand English, Spanish, or Mandarin for consenting * PHASE I: Platelets \>= 100,000/mm\^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: White blood cells (WBCs) 3,600-10,100/mm\^3 (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Total bilirubin \< 1.1 x upper limit of normal (ULN) (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Aspartate aminotransferase (AST) \< 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Alanine aminotransferase (ALT) \< 1.5 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Alkaline phosphatase (AP) \< 1.1 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Blood urea nitrogen (BUN) \< 1.25 x ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Creatinine less than or equal to the ULN (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Sodium 137-145 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Potassium 3.5-5.1 mEq/L (within 30 days prior to day 0 of protocol therapy unless otherwise stated) * PHASE I: Carbon dioxide 22-30 mmol/L …